SEC Form 4 · accession 0001104659-18-049250
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel D Burgess
Director
Period of report
Jul 31, 2018
Accepted (ET)
Aug 2, 2018 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jul 31, 2018 | P | 36,000 | $2.75 | A | 36,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Aug 1, 2018 | A | 15,000 | A | — | Aug 1, 2028 | Ordinary Shares | 15,000 | 15,000 | D |
Explanation of responses
- F1The exercise price is $2.53 per share.
- F2The option award was granted on August 1, 2018. The option award will vest in full on August 1, 2019.